WIC 2017 Day 1, Tuesday 31st October 2017

08:00 Registration Opens

08:50 Conference doors open


Welcome from Terrapinn

Opening Keynotes – Antibodies and immunotherapy

Dr Roy Baynes

Keynote: Anti PD-1 antibody therapy – a broad spectrum anticancer monotherapy and a backbone in combination therapy

  • A biologically informed screening phase 2 program has identified broad spectrum monotherapy activity
  • Pivotal trials have led to an expanding list of approved monotherapy indications
  • Biomarker research is aimed at identifying those who benefit maximally from monotherapy and those who might be studied with biologically informed combination therapies
  • An ever expanding number of highly active combinations are being advanced
Dr Puja Sapra

Keynote: Evolution of DNA damaging antibody-drug conjugates

  • From bench to bedside: explore the discovery and development Inotuzumab Ozogamicin
  • Preclinical development of novel DNA-damaging ADCs

New platforms for unmatched biologic therapeutic research, development and production

Please contact Derek Cavanagh for more information. e/derek.cavanagh@terrapinn.com t/+44 (0)207 092 1297

10:35 Networking Break

round tables

Plenary roundtable session

9 senior level tables hosted by thought leaders on key challenges and opportunities in antibody drug development. Participants are invited to join the group discussions on a topic of importance to them.
  • TABLE 1 Analytical and structural characterization of mAbs, biosimilars, ADCs, BsAbs, pAbs
  • Dr Alain Beck

    Dr Alain Beck, Senior Director, NBEs Analytical Chemistry, Centre d'Immunologie Pierre Fabre

  • TABLE 2 Providing precision histopathology for discovery and development
  • Lee Dawson

    Lee Dawson, Senior Scientist, Molecular Pathology Group, Asterand Bioscience

  • TABLE 3 Assessing target specificity of biotherapeutics
  • Dr Jim Freeth

    Dr Jim Freeth, Managing Director, Retrogenix

  • TABLE 4 Strategies for tackling cancer
  • Joern Schmitz

    Joern Schmitz, Department Head, Fraunhofer I.M.E.

  • TABLE 5 Next generation therapeutic vaccines : viral, bacterial and cell based
  • Eric Halioua

    Eric Halioua, President and Chief Executive Officer, PDC*line pharma SA

  • TABLE 6 Determining effective combinations of immune checkpoint inhibitors and biomarkers
  • Jae Sly

    Jae Sly, Director of Strategic Business Development, ACRO Biosystems Inc

  • TABLE 7 Immunotherapy for solid tumours
  • TABLE 8 Biomarkers
  • TABLE 9 Preclinical models
  • 12:20

    Speed Networking

    A fun, exciting and effective way to make a lot of initial connections (in a very different environment from the standard business networking meetings).

    12:35 Networking Lunch

    Immune checkpoint inhibitors

    Chaired by Joern Schmitz, Head, Department of Immunotherapy, Fraunhofer IME

    Dr Angie Inkyung Park

    Development and characterization of Anti-TIGIT antibody for treatment of solid cancers

    • Anti-TIGIT antibody identified by rabbit MAP Trap platform technology was able to block PVR and PVRL2 ligand binding and inhibit TIGIT signaling
    • Anti-TIGIT antibody induced tumor specific T-cell response and reduced Treg’s suppression, leading to tumor growth suppression and generation of long-term immunological memory against tumors
    • Anti-TIGIT can be combines with other ICIs for enhanced anti-tumor activity
    Prof Dr Dario Neri

    Antibody-cytokine fusions for cancer therapy

    • Antibody fusions to IL2 and to TNF
    • From the bench to Phase III clinical trials
    • Combination therapy opportunities: emerging clinical data
    • Splice isoforms of fibronectin and of tenascin-C as targets
    • New developments towards second-generation immunocytokines
    Dr Martin Treder

    Development of innate cell engagers for effective anti-tumor targeting

    • Affimed develops tetravalent, bispecific immuno-engagers for tumor-targeting of T-cells and NK-cells based on proprietary scaffolds and engager domains
    • Potency and efficacy of several immuno-engagers are currently being evaluated in clinical mono and combination trials
    • Recent developments from our NK-cell engager platform demonstrating superior efficacy over conventional Fc-based approaches will be presented
    Dr James Legg

    Targeting immune checkpoints with humabody VH therapeutics

    • Crescendo Biologics develops Humabody VH products, small highly adaptable and flexible proteins which can be developed into differentiated therapeutics
    • I will give an overview of Crescendo’s approach to developing Immune checkpoint inhibitors and products in immuno oncology
    • I will describe development of a BiParatopic Humabody targeting the checkpoint molecule PD-1

    15:30 Networking Break

    Dr Martin Welschof

    OPN-305, a first in class toll like receptor 2 (TLR2) antibody inhibitor

    • TLR2 is a key structure of the innate immune system and one of the main initiators and propagators of inflammation
    • OPN-305 is a first in class TLR2 antagonist and anti-inflammatory compound with a unique mode of action
    • The TLR2 system is associated and involved with a number of major human diseases:
    • (cancer, ischemia reperfusion injury, and autoimmune diseases, among others)
    • Pre-clinical and clinical data supports a strong value proposition in oncology
    • TLR2 seems to play a major role in the function of tumor dendritic and T regulatory cells pointing to an immune-modulatory role
    Prof Steve Anderton

    Innovative solutions for immuno-oncology drug discovery

    • Bespoke immunoassays for target validation, mode-of-action studies and combination immunotherapy design
    • In vitro and in vivo tumour-killing and immune response profiling
    • Advanced multiplex histology for visualisation and co-localisation of targets
    Dr Shane Olwill

    Costimulatory T-Cell engagement by the 4-1BB/HER2 bispecific PRS-343 for tumor localized activation of the immune system

    • Generation of the 4-1BB/HER2 bispecific, PRS-343
    • In vitro and in vivo characterisation of PRS-343
    • IND enabling studies to support clinical evaluation of PRS-343
    Dr Timo Van Den Berg

    The CD47-SIRPα axis as an innate immune checkpoint in cancer

    • Immune cell-mediated destruction of antibody-opsonized cancer cells is resticted by CD47-SIRP interactions.
    • Mechanistic insights
    • Applicability for improving antibody therapy in cancer
    Dr Frédéric Triebel

    TACTI-mel, two ACTive immunotherapies in melanoma: combination of an APC activator (IMP321 or LAG-3Ig) with Pembrolizumab

    • Enhance immune response by targeting LAG-3
    • Understand the rationale for combining an Antigen Presenting Cell (APC) activator, LAG-3Ig, with an Immune Checkpoint Inhibitor (ICI), pembrolizumab: in vitro and in vivo preclinical data
    • Evaluation of the combination in metastatic melanoma (TACTI-mel phase I trial)

    18:15 Offsite Networking Drinks

    last published: 19/Oct/17 09:45 GMT